欧州連合 - イタリア語 - EMA (European Medicines Agency)

deciphera pharmaceuticals (netherlands) b.v. - ripretinib - tumori stromali gastrointestinali - agenti antineoplastici - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.

欧州連合 - イタリア語 - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - agenti antineoplastici - sprycel è indicato per il trattamento di pazienti pediatrici con:nuova diagnosi per il cromosoma philadelphia positivo leucemia mieloide cronica in fase cronica (lmc ph+ cp) o lmc ph+ cp resistenti o intolleranti a precedente terapia tra cui imatinib. nuova diagnosi ph+ da leucemia linfoblastica acuta (all) in combinazione con la chemioterapia. sprycel è indicato per il trattamento di pazienti adulti con:nuova diagnosi philadelphia-cromosoma-positivo (ph+) di leucemia mieloide cronica (lmc) in fase cronica;cronica, accelerata o lmc in fase blastica con resistenza o intolleranza a precedente terapia tra cui imatinib mesilato;ph+ da leucemia linfoblastica acuta (all) e blastica linfoide cml con resistenza o intolleranza a precedente terapia. sprycel è indicato per il trattamento di pazienti pediatrici con:nuova diagnosi di lmc ph+ in fase cronica (lmc ph+-cp) o lmc ph+-cp resistenti o intolleranti a precedente terapia tra cui imatinib.

欧州連合 - イタリア語 - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - agenti antineoplastici - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

スイス - イタリア語 - Swissmedic (Swiss Agency for Therapeutic Products)

a.vogel ag - hyperici forato summitatis con fiori freschi estratto ethanolicum di spessore - compresse - hyperici forato summitatis con fiori freschi estratto ethanolicum di spessore corrisp. hypericinum 0.14-0.95 mg, rapporto: 1-2:1 (corrisp. massa siccata 66 mg ), excipiens pro compresso. - tenendo premuto umore - phytoarzneimittel

スイス - イタリア語 - Swissmedic (Swiss Agency for Therapeutic Products)

a.vogel ag - hyperici forato summitatis con fiori freschi estratto ethanolicum di spessore - compresse - hyperici forato summitatis con fiori freschi estratto ethanolicum di spessore corrisp. hypericinum 0.14-0.95 mg, rapporto: 1-2:1 (corrisp. massa siccata 66 mg ), excipiens pro compresso. - tenendo premuto umore - phytoarzneimittel

スイス - イタリア語 - Swissmedic (Swiss Agency for Therapeutic Products)

permamed ag - hyperici estratto di erbe ethanolicum secco - compresse rivestite con film - hyperici estratto di erbe ethanolicum secco 900 mg corrisp. hypericinum 0.9-2.7 mg, der: 3-6:1, excipiens pro compresso haze. - per lieve a moderata depressione - phytoarzneimittel

スイス - イタリア語 - Swissmedic (Swiss Agency for Therapeutic Products)

permamed ag - hyperici estratto di erbe ethanolicum secco - compresse rivestite con film - hyperici estratto di erbe ethanolicum secco 900 mg corrisp. hypericinum 0.9-2.7 mg, der: 3-6:1, excipiens pro compresso haze. - per lieve a moderata depressione - phytoarzneimittel

欧州連合 - イタリア語 - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. vedi sezioni 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.

スイス - イタリア語 - Swissmedic (Swiss Agency for Therapeutic Products)

teva pharma ag - dasatinibum - compresse rivestite con film - dasatinibum 20 mg ut dasatinibum monohydricum, lactosum monohydricum 26.261 mg, cellulosum microcristallinum, hydroxypropylcellulosum, carmellosum natricum conexum corresp. natrium max. 0.29 mg, magnesii stearas, Überzug: hypromellosum, triacetinum, e 171, pro compresso obducto. - philadelphiachromosom positivi cronica mieloide leucemia; philadelphiachromosom positivi per la leucemia linfatica acuta - synthetika

スイス - イタリア語 - Swissmedic (Swiss Agency for Therapeutic Products)

teva pharma ag - dasatinibum - compresse rivestite con film - dasatinibum 50 mg ut dasatinibum monohydricum, lactosum monohydricum 65.653 mg, cellulosum microcristallinum, hydroxypropylcellulosum, carmellosum natricum conexum corresp. natrium max. 0.72 mg, magnesii stearas, Überzug: hypromellosum, triacetinum, e 171, pro compresso obducto. - philadelphiachromosom positivi cronica mieloide leucemia; philadelphiachromosom positivi per la leucemia linfatica acuta - synthetika